[go: up one dir, main page]

AR060931A1 - Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion - Google Patents

Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion

Info

Publication number
AR060931A1
AR060931A1 ARP070102085A ARP070102085A AR060931A1 AR 060931 A1 AR060931 A1 AR 060931A1 AR P070102085 A ARP070102085 A AR P070102085A AR P070102085 A ARP070102085 A AR P070102085A AR 060931 A1 AR060931 A1 AR 060931A1
Authority
AR
Argentina
Prior art keywords
nicotine
administration
coating
coated
preparation
Prior art date
Application number
ARP070102085A
Other languages
English (en)
Original Assignee
Mcneil Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38694149&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR060931(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mcneil Ab filed Critical Mcneil Ab
Publication of AR060931A1 publication Critical patent/AR060931A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465Nicotine; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Formas de dosificacion oral recubiertas para la administracion de nicotina en cualquier forma a un sujeto mediante la rápida administracion intraoral de nicotina, que comprenden al menos un nucleo, nicotina en cualquier forma y/o un agente imitador de la nicotina, al menos una capa de recubrimiento y opcionalmente al menos uno o varios aditivos adicionales, en donde dicha al menos una capa de recubrimiento contiene buffer, en donde se usa al menos trometamol como agente de buffer. También se contempla un método para la administracion de nicotina en cualquier forma, un método para la reduccion de la necesidad de fumar o usar tabaco, así como un método para producir dicho producto recubierto y el uso de dicho producto para obtener una rápida captacion intraoral de nicotina. Reivindicacion 24: Un dispositivo para administrar nicotina en cualquier forma a un sujeto, que comprende un producto recubierto de acuerdo con cualquiera de las reivindicaciones 1-23 y al menos otro medio o método adicional para obtener la reduccion de la necesidad de fumar o usar tabaco. Reivindicacion 38: Una goma de mascar recubierta que contiene nicotina, donde el nucleo de la goma de mascar comprende nicotina en cualquier forma, una base de goma, trometamol, uno o varios endulzantes y uno o varios saborizantes, y donde el recubrimiento es un recubrimiento duro que comprende nicotina en cualquier forma, trometamol, uno o varios endulzantes y gelatina.
ARP070102085A 2006-05-16 2007-05-15 Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion AR060931A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0601090 2006-05-16

Publications (1)

Publication Number Publication Date
AR060931A1 true AR060931A1 (es) 2008-07-23

Family

ID=38694149

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070102085A AR060931A1 (es) 2006-05-16 2007-05-15 Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion

Country Status (16)

Country Link
US (1) US20070269492A1 (es)
EP (1) EP2023928A4 (es)
JP (1) JP5254213B2 (es)
KR (1) KR101414063B1 (es)
CN (1) CN101472591A (es)
AR (1) AR060931A1 (es)
AU (1) AU2007250589B2 (es)
BR (1) BRPI0712068A2 (es)
CA (1) CA2652500C (es)
MX (1) MX2008014726A (es)
NO (1) NO20084987L (es)
NZ (1) NZ572758A (es)
RU (1) RU2448707C2 (es)
TW (1) TW200810755A (es)
WO (1) WO2007133141A1 (es)
ZA (1) ZA200810618B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US8642016B2 (en) 2006-07-21 2014-02-04 Jsrnti, Llc Medicinal delivery system, and related methods
KR101122469B1 (ko) * 2007-04-02 2012-07-12 파킨슨즈 인스티튜트 처치 치료의 부작용을 감소시키기 위한 방법 및 조성물
GB2468424B (en) * 2007-04-02 2011-11-09 Parkinson S Inst Methods and compositions for reduction of side effects of therapeutic treatments
US20080286341A1 (en) * 2007-05-16 2008-11-20 Sven-Borje Andersson Buffered coated nicotine containing products
AR071420A1 (es) * 2008-05-01 2010-06-16 Smithkline Beecham Corp Composicion de pastilla para chupar oral que comprende un principio activo de nicotina y procedimiento para fabricarla
AU2013219211B2 (en) * 2008-05-01 2016-05-12 North Star OpCo Limited Nicotine lozenge compositions
ES2401912T3 (es) 2008-09-17 2013-04-25 Siegfried Ltd. Granulado que contiene nicotina
JP2012505878A (ja) 2008-10-14 2012-03-08 マクニール アーベー 複数部分口内剤形及びその使用
DK2198865T3 (da) * 2008-12-19 2012-01-16 Siegfried Ltd Nikotinholdigt produkt
US20100247586A1 (en) * 2009-03-27 2010-09-30 Andreas Hugerth Multi-Portion Intra-Oral Dosage Form With Organoleptic Properties
WO2010145653A1 (en) * 2009-06-19 2010-12-23 Fertin Pharma A/S Buffered gum base for high ph release
WO2011101860A1 (en) * 2010-02-18 2011-08-25 Jatin Vasant Thakkar Nicotine-containing soft gelatin pastilles
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
EP2729148A4 (en) 2011-07-06 2015-04-22 Parkinson S Inst COMPOSITIONS AND METHOD FOR THE TREATMENT OF SYMPTOMS IN PATIENTS WITH MORBUS PARKINSON
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US20130177646A1 (en) * 2012-01-05 2013-07-11 Mcneil Ab Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9044035B2 (en) 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
FR2993778B1 (fr) * 2012-07-30 2016-06-17 Pf Medicament Pastilles a cinetiques multiples de liberation de principes actifs
CN102926277B (zh) * 2012-11-14 2015-05-20 湖南中烟工业有限责任公司 一种β-环糊精-g-乳酸共聚物的应用
US9375033B2 (en) 2014-02-14 2016-06-28 R.J. Reynolds Tobacco Company Tobacco-containing gel composition
EP3250258A4 (en) 2015-01-28 2018-09-05 Chrono Therapeutics, Inc. Drug delivery methods and systems
US10679516B2 (en) 2015-03-12 2020-06-09 Morningside Venture Investments Limited Craving input and support system
US20170172995A1 (en) * 2015-09-08 2017-06-22 Venkateswara Rao Repaka Pharmaceutical compositions of Nicotine and process for preparation thereof
US20170165252A1 (en) 2015-12-10 2017-06-15 Niconovum Usa Inc. Protein-enriched therapeutic composition
AU2018205529B2 (en) 2017-01-06 2023-08-10 Morningside Venture Investments Limited Transdermal drug delivery devices and methods
CA3085062C (en) * 2017-12-08 2022-08-16 Fertin Pharma A/S Nicotine tablet
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
MX2021000466A (es) 2018-07-13 2021-03-25 Mcneil Ab Goma de mascar que comprende nicotina.
MA54245A (fr) 2018-11-16 2022-02-23 Morningside Venture Investments Ltd Système d'administration transdermique de médicaments à régulation thermique
US20230053622A1 (en) 2020-01-15 2023-02-23 Mcneil Ab Lozenge
SE544672C2 (en) * 2020-05-07 2022-10-11 Liw Innovation Ab New compositions for oral or nasal use
EP4419103A1 (en) * 2021-10-21 2024-08-28 McNeil AB Nicotine chewing gum

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901248A (en) * 1970-07-22 1975-08-26 Leo Ab Chewable smoking substitute composition
US3877468A (en) * 1970-07-22 1975-04-15 Leo Ab Chewable tobacco substitute composition
US3845217A (en) * 1972-11-16 1974-10-29 Helsingborg L Ab Buffered smoking substitute compositions
GB8301659D0 (en) * 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
US5783207A (en) * 1985-05-01 1998-07-21 University Of Utah Research Foundation Selectively removable nicotine-containing dosage form for use in the transmucosal delivery of nicotine
GB8615676D0 (en) * 1986-06-26 1986-07-30 Stoppers Co Ltd Nicotine containing lozenge
US5004651A (en) * 1989-01-24 1991-04-02 Abbott Laboratories Stabilizing system for solid dosage forms
US5824334A (en) * 1989-09-05 1998-10-20 University Of Utah Research Foundation Tobacco substitute
US5167242A (en) * 1990-06-08 1992-12-01 Kabi Pharmacia Aktiebolaq Nicotine-impermeable container and method of fabricating the same
EP0620706A1 (en) * 1992-01-06 1994-10-26 E.I. Du Pont De Nemours And Company Tablet formulation with internal desiccant
SE9303574D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Composition for drug delivery and method the manufacturing thereof
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5810081A (en) * 1997-02-24 1998-09-22 Cobb; Delwin E. Wear structure for bore hole separation device
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030175349A1 (en) * 2001-01-30 2003-09-18 Council Of Scientific And Industrial Research Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient
SE0102197D0 (sv) * 2001-06-20 2001-06-20 Pharmacia Ab New product and use and manufacture thereof
US20040037879A1 (en) * 2001-11-02 2004-02-26 Adusumilli Prasad S. Oral controlled release forms useful for reducing or preventing nicotine cravings
AU2003227691B2 (en) * 2002-05-03 2008-05-15 Hexal Ag Stable pharmaceutical formulation for a combination of a statin and an ace inhibitor
US7157100B2 (en) * 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system
US20030049307A1 (en) * 2002-08-15 2003-03-13 Gyurik Robert J. Pharmaceutical composition
US20040052851A1 (en) * 2002-09-16 2004-03-18 Graff Allan H. Modified release oral dosage form

Also Published As

Publication number Publication date
TW200810755A (en) 2008-03-01
MX2008014726A (es) 2009-02-04
NO20084987L (no) 2009-02-16
EP2023928A1 (en) 2009-02-18
NZ572758A (en) 2011-01-28
KR101414063B1 (ko) 2014-07-18
US20070269492A1 (en) 2007-11-22
CN101472591A (zh) 2009-07-01
AU2007250589B2 (en) 2011-04-14
CA2652500A1 (en) 2007-11-22
EP2023928A4 (en) 2012-08-29
CA2652500C (en) 2014-07-29
RU2008149508A (ru) 2010-06-27
WO2007133141A1 (en) 2007-11-22
JP2009537514A (ja) 2009-10-29
BRPI0712068A2 (pt) 2012-01-17
AU2007250589A1 (en) 2007-11-22
KR20090024161A (ko) 2009-03-06
ZA200810618B (en) 2010-02-24
RU2448707C2 (ru) 2012-04-27
JP5254213B2 (ja) 2013-08-07

Similar Documents

Publication Publication Date Title
AR060931A1 (es) Producto farmaceutico recubierto para la administracion intraoral de nicotina y su uso y elaboracion
AR034527A1 (es) Nuevo producto y uso y fabricacion del mismo
AR066585A1 (es) Nuevo producto y su uso y fabricacion
AR060932A1 (es) Producto y su uso y elaboracion
DK1471890T3 (da) Farmaceutisk doseringsform til mukös afgivelse
EE05287B1 (et) Tsklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
ATE374601T1 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein- wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
AR076153A1 (es) Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones
WO2006100075A3 (en) Use of an artificial sweetener to enhance absorption of nicotine
FI3782612T3 (fi) Sytidiinianalogien oraalisia formulaatioita ja menetelmiä niiden käyttämiseksi
IS7142A (is) Lyfjasamsetningar, sem innihalda morfíngerandaefni, ásamt losanlegu en hömdu mótlyfi
AR071850A1 (es) Gomas de mascar en forma de tableta
ATE330589T1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
JP2008505857A5 (es)
CY1111433T1 (el) Φαρμακευτικο τυποποιημενο παρασκευασμα δεσιταβινης
MX2010006284A (es) Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal.
CY1111369T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη
AR044383A1 (es) Composiciones farmaceuticas de vareniclina
JP2019514990A5 (es)
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
DE60336225D1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
ATE398441T1 (de) Octenidinhaltige lutschtabletten gegen entzündliche erkrankungen des mund- und rachenraums
UY28457A1 (es) Nueva composición
DE602005021115D1 (de) Verfahren und zusammensetzungen zur oralen fts-abgabe

Legal Events

Date Code Title Description
FA Abandonment or withdrawal